| Characteristics | Effectiveness | Side effects | Convenience | Global satisfaction | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Coeff. | p | Mean | SD | Coeff. | p | Mean | SD | Coeff. | p | Mean | SD | Coeff. | P | |
| Age (years) | 0.05 | .221 (a) | −0.1 | .029 (a) | −0.04 | .403 (a) | −0.06 | .186 (a) | ||||||||
| Sex | ||||||||||||||||
| Male | 64.6 | 13.8 | .872 (b) | 97.9 | 8.1 | .673 (b) | 57.2 | 14.8 | .244 (b) | 66.8 | 14.8 | .808 (b) | ||||
| Female | 66.7 | 15.7 | 100 | 47.2 | 3.9 | 64.3 | 10.1 | |||||||||
| BMI (kg/m2) | 0.0 | .963 (a) | 0.02 | .633 (a) | 0.04 | .388 (a) | 0.04 | .348 (a) | ||||||||
| Disease duration (Months) | −0.03 | .443 (a) | −0.09 | .05 (a) | 0.01 | .892 (a) | −0.06 | .200 (a) | ||||||||
| Severity | ||||||||||||||||
| Severe | 63.9 | 13.4 | .032 (c) | 97.7 | 8.4 | .657 (c) | 56.9 | 14.9 | .368 (c) | 66.2 | 14.6 | .078 (c) | ||||
| Moderate | 69.6 | 15.3 | 98.6 | 5.4 | 57.7 | 13.9 | 70.2 | 15.4 | ||||||||
| Mild | 72.2 | 18.8 | 100 | 0.0 | 63.9 | 17.1 | 72.3 | 19.6 | ||||||||
| Inhibitor | ||||||||||||||||
| Yes | 50.0 | 0.0 | .029 (b) | 100 | 0.0 | .603 (b) | 46.3 | 6.4 | .144 (b) | 52.4 | 4.1 | .051 (b) | ||||
| No | 64.7 | 13.8 | 97.8 | 8.1 | 57.2 | 14.8 | 66.9 | 14.8 | ||||||||
| Arthropathy | ||||||||||||||||
| Yes | 63.9 | 14.0 | .173 (b) | 97.5 | 8.7 | .1 (b) | 56.8 | 15 | .594 (b) | 66.3 | 14.5 | .39 (b) | ||||
| No | 66.3 | 13.3 | 98.6 | 6.6 | 57.8 | 13.6 | 67.9 | 15.2 | ||||||||
| Central venous catheter | ||||||||||||||||
| Yes | 100 | 0.0 | .499 (b) | 53.3 | 10.1 | .587 (b) | 61.4 | 3.9 | .322 (b) | |||||||
| No | 97.8 | 8.1 | 57.1 | 14.8 | 66.8 | 14.9 | ||||||||||
| Duration of Treatment (months) | 0.03 | .501 (a) | 0.11 | .012 (a) | 492 | 97.4 | −0.02 | .669 (a) | −0.01 | .804 (a) | ||||||
| Treatment methods | ||||||||||||||||
| Prophylaxis | 64.1 | 12.7 | .053 (b) | 98.2 | 7 | .315 (c) | 57.7 | 15.1 | .184 (b) | 66.8 | 14.8 | .605 (b) | ||||
| On demand | 67.8 | 15.3 | 98.3 | 7.5 | 58.1 | 14.5 | 67.8 | 15.1 | ||||||||
| Both | 62.9 | 14.4 | 96.8 | 10.5 | 54.8 | 14.2 | 65.7 | 14.6 | ||||||||
| RCD type | ||||||||||||||||
| PDC syringe | 66.0 | 14.7 | .753 (b) | 94.7 | 10.1 | <.0001 (c) | 62.6 | 17.8 | .067 (b) | 65.6 | 14 | .958 (b) | ||||
| Pref. syringe connected with a vial | 63.7 | 14.7 | 94.9 | 13.7 | 57.1 | 14.4 | 67.2 | 15.1 | ||||||||
| Two connected vials | 64.7 | 13.6 | 98.7 | 6.1 | 56.7 | 14.5 | 66.8 | 14.8 | ||||||||
| Diluent volume | ||||||||||||||||
| ≤5 ml | 64.9 | 13.8 | .344 (b) | 97.9 | 7.9 | .763 (c) | 57.2 | 14.8 | .147 (b) | 66.8 | 14.7 | .23 (b) | ||||
| 6–10 ml | 62.3 | 9.5 | 98.7 | 3.6 | 62.5 | 13.6 | 72.5 | 13.4 | ||||||||
| 11–20 ml* | 50.0 | NA | 100 | 38.9 | 50 | |||||||||||
| Others | 61.3 | 16.0 | 95.8 | 12.1 | 53.3 | 14.8 | 64 | 16.4 | ||||||||
| Number of vials per injection | ||||||||||||||||
| 1 | 63.3 | 11.7 | .278 (b) | 96.5 | 10 | .505 (c) | 57.5 | 15.5 | .116 (b) | 67.6 | 14 | .187 (b) | ||||
| 2 | 64.4 | 13.7 | 98.3 | 6.5 | 58.4 | 14.7 | 67.3 | 14.8 | ||||||||
| 3 | 65.9 | 13.4 | 97.8 | 9.1 | 56.5 | 14.1 | 66.9 | 14.1 | ||||||||
| ≥4 | 62.8 | 17.4 | 96.9 | 9.7 | 52.1 | 16.1 | 62.3 | 17.5 | ||||||||
| Frequency of drug administration | ||||||||||||||||
| ≥Twice a week | 63.4 | 13.2 | .001 (b) | 97.5 | 8.7 | .226 (c) | 56.7 | 14.5 | .540 (b) | 66.3 | 14.5 | .011 (b) | ||||
| Once a week | 64.6 | 13.0 | 98.2 | 7.4 | 57.2 | 15.2 | 64.8 | 14 | ||||||||
| ≤Twice a month | 73.0 | 16.1 | 99.6 | 2.6 | 59.7 | 15.8 | 72.7 | 16.7 | ||||||||
| Dose of treatment | 505 | 100 | −0.02 | .719 (a) | −0.01 | .871 (a) | −0.01 | .826 (a) | 0.02 | .715 (a) | ||||||
| Number of bleeding events | −0.14 | .002 (a) | −0.08 | .068 (a) | −0.1 | 0.03 (a) | −0.07 | .126 (a) | ||||||||
(a) p‐value by Spearman's correlation analysis; (b) p‐value by Mann‐Whitney U test; (c) p‐value by Kruskal‐Wallis test.
Abbreviations: BMI, body mass index; PDC, prefilled dual chamber; Pref., prefilled; RCD, reconstitution device.
*
N = 1.